New Zealand Gazette – 1997 – No. 54

Page 1254

✨ Health and Education Notices



1254 NEW ZEALAND GAZETTE No. 54

executed on the 15th day of May 1997. A copy of the supplementary agreement is available for inspection without charge by any member of the public at the district office of the Ministry of Education, 116 Victoria Avenue, Wanganui.

Dated at Wellington this 16th day of May 1997.

KATHY PHILLIPS, Senior Manager, National Operations.

g03396

Health

Medicines Act 1981

Provisional Consent to the Distribution of a New Medicine

Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Irinotecan hydrochloride trihydrate 20 mg/mL in 5 mL Injection, vial Pharmacia & Upjohn Company, Kalamazoo, Michigan, United States of America Camptosar

Note: This consent is valid for 2 years from the date of publication of this notice.

Dated this 20th day of May 1997.

G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on the 20th day of February 1997.

g03353

Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Polyhexanide 0.005% w/v in 100 mL, 250 mL, 380 mL Solution, contact lens Sauflon Pharmaceuticals Limited, Ashford, Kent, United Kingdom All In One
Amikacin sulphate equivalent to 500 mg (500 000 IU) amikacin in 2 mL Injection, vial David Bull Laboratories Limited, Mulgrave North, Victoria, Australia Amikacin
Minoxidil 20 mg/mL in 60 mL Solution, topical Nu-Pharm Inc., Richmond Hill, Ontario, Canada Apo-Gain
Doxorubicin hydrochloride 2 mg/mL as pegylated liposomal doxorubicin hydrochloride in 10 mL Infusion, concentrate, vial Ben Venue Laboratories Inc., Bedford, Ohio, United States of America Caelyx
Etoposide 100 mg in 5 mL Solution, infusion, vial Thissen Laboratories SA., Braine-L'Alleud, Belgium Etoposide for Injection
Toremifene citrate 88.5 mg equivalent to 60 mg toremifene Tablet Orion Corporation Farmos, Turku, Finland Fareston
Isosorbide mononitrate 60 mg Tablet, modified release Wyeth Australia Pty Limited, Smithfield, New South Wales, Australia Monotrate
Dornase alfa 1 mg/mL (1000 U/mL) Solution, inhaled Automated Liquid Packaging, Woodstock, Illinois, United States of America and Genentech Inc., South San Francisco, California, United States of America Pulmozyme
Chlorpheniramine maleate 1 mg, dextromethorphan hydrobromide 7.5 mg, pseudoephedrine hydrochloride 15 mg per 5 mL in 25 mL, 100 mL, 200 mL Elixir Wyeth Australia Pty Limited, Smithfield, New South Wales, Australia Robitussin Children's Night Relief
Disodium tiludronate 200 mg Tablet Sanofi Winthrop Industrie, Ambares, France Skelid


Next Page →

PDF embedding disabled (Crown copyright)

View this page online at:


VUW Te Waharoa — PDF NZ Gazette 1997, No 54


NZLII — PDF NZ Gazette 1997, No 54




✨ LLM interpretation of page content

🎓 Supplementary Integration Agreement for St Peter’s College (continued from previous page)

🎓 Education, Culture & Science
16 May 1997
Integration Agreement, St Peter’s College, Palmerston North
  • KATHY PHILLIPS, Senior Manager, National Operations

🏥 Provisional Consent to the Distribution of a New Medicine

🏥 Health & Social Welfare
20 May 1997
Medicines, Provisional Consent, Irinotecan hydrochloride trihydrate, Camptosar
  • G. R. BOYD, Chief Advisor, Regulation and Safety

🏥 Consent to the Distribution of New Medicines

🏥 Health & Social Welfare
20 May 1997
Medicines, Consent, Polyhexanide, Amikacin, Minoxidil, Doxorubicin, Etoposide, Toremifene, Isosorbide, Dornase alfa, Chlorpheniramine, Disodium tiludronate
  • G. R. BOYD, Chief Advisor, Regulation and Safety